(Q38561004)

4 September 2017

title

Persistent suppression of the pituitary-gonadal system in female rats by three-month depot injectable microspheres of leuprorelin acetate (English)

1 reference

4 September 2017

1 reference

1 reference

Okada H

1

1 reference

4 September 2017

Doken Y

series ordinal

2

1 reference

4 September 2017

Ogawa Y

series ordinal

3

1 reference

4 September 2017

language of work or name

English

0 references

publication date

1 October 1996

1 reference

Journal of Pharmaceutical Sciences

4 September 2017

published in

1 reference

4 September 2017

volume

85

1 reference

4 September 2017

issue

10

1 reference

4 September 2017

page(s)

1044-1048

1 reference

Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers

4 September 2017

cites work

1 reference

7 January 2021

Sustained suppression of the pituitary-gonadal axis by leuprorelin three-month depot microspheres in rats and dogs

1 reference

7 January 2021

Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules

1 reference

7 January 2021

A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid

1 reference

7 January 2021

Biodegradable microspheres in drug delivery

1 reference

7 January 2021

Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals

1 reference

7 January 2021

Sustained pharmacological activities in rats following single and repeated administration of once-a-month injectable microspheres of leuprolide acetate

1 reference

7 January 2021

Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results

1 reference

7 January 2021

Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group

1 reference

7 January 2021

A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata

1 reference

7 January 2021

Long-term management of adenomyosis with a gonadotropin-releasing hormone agonist: a case report

1 reference

7 January 2021

Depot leuprolide acetate dosage for sexual precocity

1 reference

7 January 2021

A dose finding study of a super long-acting luteinizing hormone-releasing hormone analog (leuprolide acetate depot, TAP-144-SR) in the treatment of central precocious puberty. The TAP-144-SR CPP Study Group

1 reference

7 January 2021

Two-year results of treatment with depot leuprolide acetate for central precocious puberty

1 reference

7 January 2021

Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate

1 reference

7 January 2021

Desensitization of gonadotropin-releasing response following vaginal consecutive administration of leuprolide in rats.

1 reference

7 January 2021

Identifiers

DOI

10.1021/JS960123A

1 reference

release_ukhk7xcunfgqncnwsbr2svoeuq

4 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ukhk7xcunfgqncnwsbr2svoeuq

24 November 2022

mapped directly with Wikidata item

1 reference